THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
TORONTO, March 20, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is happy to announce that it has closed an preliminary tranche (“First Tranche”) of the providing introduced on March 10, 2026 and March 11, 2026 (collectively, the “Announcement NRs”) and has issued 3,750 Debenture Items (as outlined within the Announcement NRs) for $3,750,000.
The Firm will use the proceeds from the First Tranche for the continuing improvement of the Firm’s enterprise mannequin and for basic working capital functions.
One director of the Firm (the “Director Subscriber”) participated within the Providing (as outlined within the Announcement NRs) and subscribed for Debenture Items representing mixture gross proceeds of $300,000. The participation by the Director Subscriber within the Providing constitutes a “related party transaction” as outlined underneath Multilateral Instrument 61-101 – Safety of Minority Safety Holders in Particular Transactions (“MI 61-101”). The Firm is counting on the exemptions from the formal valuation and minority shareholder approval necessities of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the truthful market worth of the subject material of, nor the truthful market worth of the consideration for, the transaction exceeds 25% of the Firm’s market capitalization, as decided in accordance with MI 61-101. The Firm didn’t file a cloth change report in respect of the associated get together elements of the Director Subscriber’s participation within the Providing at the very least 21 days earlier than the closing of the Providing, which the Firm deems affordable within the circumstances so as to expedite the completion of the Providing.
Debt Settlement
More Read
As well as, the Firm has accomplished an preliminary batch of the Debt Settlement (as outlined within the Announcement NRs) by issuing an mixture of 370,457 Class B subordinate voting shares within the Firm (every, a “Class B Share”) to settle roughly $1,117,727 of debt owed to sure arm’s size collectors and insiders of the Firm.
The participation by insiders of the Firm within the Debt Settlement constitutes a “related party transaction” as outlined underneath Multilateral Instrument 61-101 – Safety of Minority Safety Holders in Particular Transactions (“MI 61-101”). The Firm is counting on the exemptions from the formal valuation and minority shareholder approval necessities of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the truthful market worth of the subject material of, nor the truthful market worth of the consideration for, the transaction exceeds 25% of the Firm’s market capitalization, as decided in accordance with MI 61-101. The Firm didn’t file a cloth change report in respect of the associated get together elements of the Debt Settlement at the very least 21 days earlier than the closing of the Debt Settlement, which the Firm deems affordable within the circumstances so as to expedite the completion of the Debt Settlement.
All quantities on this press launch are expressed in Canadian {dollars}.
More Read
The securities described herein haven’t been, nor will they be, registered underneath the US Securities Act of 1933, as amended, and is probably not provided or offered in the US or to, or for the account or good thing about, U.S. individuals absent registration or an relevant exemption from the registration necessities. This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase nor shall there be any sale of the securities in any State during which such provide, solicitation or sale could be illegal.
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical firm devoted to constructing a portfolio of progressive belongings and biotech options for the therapy of difficult neurodegenerative and metabolic problems and alcohol misuse problems with drug candidates in several levels of improvement. By means of its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is concentrated on the analysis and improvement of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity proven to stop and reverse myelin degradation, the underlying mechanism of a number of sclerosis, in preclinical fashions. Quantum BioPharma invented UNBUZZD™ and spun out its OTC model to an organization, Celly Diet Corp. (“Celly Nutrition”), led by business veterans. Quantum BioPharma retains possession of 25.71% (as of June 30, 2024) of Celly Diet at www.unbuzzd.com. The settlement with Celly Diet additionally contains royalty funds of seven% of gross sales from unbuzzd™ till funds to Quantum BioPharma complete $250 million. As soon as $250 million is reached, the royalty drops to three% in perpetuity. Moreover, Quantum BioPharma retains a big tax loss carry ahead of roughly C$130 million and might be utilized sooner or later to offset tax payable obligations in opposition to future earnings. Quantum BioPharma retains 100% of the rights to develop related product or various formulations particularly for pharmaceutical and medical makes use of.
Ahead-Wanting Data
Ahead-looking data on this press launch is predicated on sure assumptions and anticipated future occasions, together with however not restricted to: the Firm has the power to finish further tranches of the Providing and the Debt Settlement.
These statements contain recognized and unknown dangers, uncertainties and different elements, which can trigger precise outcomes, efficiency or achievements to vary materially from these expressed or implied by such statements, together with however not restricted to: dangers regarding the Firm’s enterprise and operations typically; and the reader is urged to confer with further data regarding Quantum BioPharma, together with its annual data kind, which will be positioned on the SEDAR+ web site at www.sedarplus.ca and on the EDGAR part of the US Securities and Trade Fee’s web site at www.sec.gov for a extra full dialogue of such threat elements and their potential results.
More Read
Readers are cautioned that the foregoing record is just not exhaustive. Readers are additional cautioned to not place undue reliance on forward-looking statements, as there will be no assurance that the plans, intentions or expectations upon which they’re positioned will happen. Such data, though thought-about affordable by administration on the time of preparation, could show to be incorrect and precise outcomes could differ materially from these anticipated.
Ahead-looking statements contained on this press launch are expressly certified by this cautionary assertion and mirror the Firm’s expectations as of the date hereof and are topic to alter thereafter. The Firm undertakes no obligation to replace or revise any forward-looking statements, whether or not because of new data, estimates or opinions, future occasions or outcomes or in any other case or to clarify any materials distinction between subsequent precise occasions and such forward-looking data, besides as required by relevant regulation.
Contacts:
